Dr. Péter Ferdinandy, MD, PhD, MBA
Vice-Rector

Citizenship:
Hungarian

Date and place of birth:
1966, Békéscsaba

Email: sci.vicerector@semmelweis-univ.hu

Current positions

  • 2018 – ongoing: Vice-Rector for Science and Innovations, Semmelweis University
  • 2011 – ongoing: Professor & Director, Department of Pharmacology and Pharmacotherapy, Medical Faculty – Semmelweis University, Budapest, Hungary
  • 2005 – 2019: Professor of Biochemistry (part-time), Head of the Cardiovascular Research Group – University of Szeged, Hungary
  • 2003 – ongoing: Founder and CEO of Pharmahungary Group,  Szeged, Hungary (spin-off companies)

Education and Scientific degrees

  • 2004: DSc in medical sciences, Hungarian Academy of Sciences
  • 2000-2004: MBA (Masters of Business Administration, Finance and Quality management), Budapest Technical University, Hungary
  • 1999: Designation as registered Clinical-Pharmacologist
  • 1997-1999: Postdoctoral training, Dept Pharmacology, University of Alberta, Edmonton, Canada1995 December 
  • 1991-1995: PhD training, Departments of Physiology and Biochemistry, University of Szeged, Hungary
  • 1991: MD diploma (score: excellent, “summa cum laude”)
  • 1985-1991: University of Szeged, Hungary

Teaching experience

  • 2004 – ongoing: Lecturer in Pharmacology, Semmelweis University, Budapest
  • 1993 – ongoing: Lecturer in Biochemistry, University of Szeged, Hungary
  • 1998-1999: Lecturer in Pharmacology, University of Alberta, Edmonton, Canada
  • 1991-1994: Lecturer in Physiology, University of Szeged, Hungary

Scholarships, fellowships

  • 1989-1991: Scholarship of Hungarian Republic
  • 1997-1999: Postdoc Fellow, MRC Canada, University of Alberta, Canada
  • 2001-2005: Szechenyi professorship, Hungarian Academy of Sciences
  • 2013-2014: Szentagothai professorship, National Excellence Program

Major awards

First prize, Young Investigator Award 1999, International Society for Heart Research

Major leadership positions at international scientific organizations

  • 2012-2014: President, International Society for Heart Research, European Section
  • 2014-2016: Chairman, Working Group Cell Biology of the Heart, European Cardiology Society
  • 2019-2023: President, Hungarian Society of Experimental and Clinical Pharmacology

Editorial board memberships

  • Editor-in-Chief: British Journal of Pharmacology, from Jan 1, 2023
  • Br J Pharmacol (Reviews Editor, Guest Editor, impakt factor 4.9)
  • J Mol Cell Cardiol (Editor, impakt factor 5.1)
  • Basic Res Cardiol (Editor, impakt factor 5.9)
  • J Pharmacol Tox Methods (Editor, impakt factor 2.2)
  • Vascular Pharmacology (Editor, impakt factor 3.7)

Languages

  • Native language: Hungarian
  • English (fluent)
  • German (basic understanding)

Scientometric data

  • Number of papers in international peer-reviewed journals: over 340 (source: PubMed)
  • Cumulative impact factor of full papers: over 1600
  • Total number of citations: over 23000, Hirsch index: 75 (source: Google Scholar)
  • Patent families: 6, software developments: 3 on the market
  • Listed on HIGHLYCITED researchers in 2014; 2017, 2020, 2021, 2022, 2023 (list of the most influential “highly cited” scientists)